Physician profile
John C Forstall
NPI 1326571720
$4,716.51
in general payments reported to CMS, 2019-2025
26 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.95 · 2020: $29.78 · 2021: $403 · 2022: $930 · 2023: $686 · 2024: $2,470 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,768 · Food and Beverage: $1,500 · Education: $66.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,768.29 |
| Food and Beverage | $1,499.76 |
| Education | $66.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,271.99 | 2024 | Illumisite, Arcpoint |
| Pulmonx Corporation | $1,127.20 | 2024-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Abbvie INC. | $435.09 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.47 | 2021-2025 | Ofev, Jascayd |
| Mallinckrodt Hospital Products INC. | $213.63 | 2022-2023 | Acthar |
| Glaxosmithkline, LLC. | $210.90 | 2021-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $160.58 | 2020-2024 | Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $147.48 | 2021-2025 | Dupixent |
| Noah Medical Corporation | $132.66 | 2023 | |
| Pfizer INC. | $126.38 | 2021 | |
| Merck Sharp & Dohme LLC | $118.34 | 2022-2023 | Zerbaxa |
| Bayer Healthcare Pharmaceuticals INC. | $79.81 | 2022-2023 | |
| Genzyme Corporation | $69.94 | 2021-2023 | |
| Insmed, INC. | $44.83 | 2022-2024 | Arikayce |
| Intuitive Surgical, INC. | $37.42 | 2023 | Da Vinci Surgical System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $34.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.38 | 2023 | Glassia |
| Actelion Pharmaceuticals US, INC. | $25.95 | 2023 | Uptravi |
| Astellas Pharma US INC | $21.89 | 2021 | |
| Daiichi Sankyo INC. | $18.95 | 2019 | |
| Inari Medical, INC. | $18.85 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Livanova USA, INC. | $18.51 | 2022 | |
| Genentech USA, INC. | $17.96 | 2022 | |
| Bard Peripheral Vascular, INC. | $14.76 | 2021 | |
| Avanos Medical | $14.14 | 2021 | |
| Novo Nordisk INC | $13.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Forstall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.